Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.

Berger LA, Janning M, Velthaus JL, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S.

J Thorac Oncol. 2018 Sep 8. pii: S1556-0864(18)33041-7. doi: 10.1016/j.jtho.2018.08.2025. [Epub ahead of print] No abstract available.

PMID:
30205165
2.

Clinical relevance of cytoskeleton associated proteins for ovarian cancer.

Schiewek J, Schumacher U, Lange T, Joosse SA, Wikman H, Pantel K, Mikhaylova M, Kneussel M, Linder S, Schmalfeldt B, Oliveira-Ferrer L, Windhorst S.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2195-2205. doi: 10.1007/s00432-018-2710-9. Epub 2018 Aug 9.

PMID:
30094535
3.

Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients.

Joosse SA, Souche FR, Babayan A, Gasch C, Kerkhoven RM, Ramos J, Fabre JM, Riethdorf S, König A, Wikman H, Alix-Panabières C, Pantel K.

Clin Chem. 2018 Oct;64(10):1505-1512. doi: 10.1373/clinchem.2018.289819. Epub 2018 Jul 20.

PMID:
30030273
4.

Stromal Caveolin-1 and Caveolin-2 Expression in Primary Tumors and Lymph Node Metastases.

Gerstenberger W, Wrage M, Kettunen E, Pantel K, Anttila S, Steurer S, Wikman H.

Anal Cell Pathol (Amst). 2018 Apr 10;2018:8651790. doi: 10.1155/2018/8651790. eCollection 2018.

5.

Strong fascin expression promotes metastasis independent of its F-actin bundling activity.

Heinz LS, Muhs S, Schiewek J, Grüb S, Nalaskowski M, Lin YN, Wikman H, Oliveira-Ferrer L, Lange T, Wellbrock J, Konietzny A, Mikhaylova M, Windhorst S.

Oncotarget. 2017 Nov 1;8(66):110077-110091. doi: 10.18632/oncotarget.22249. eCollection 2017 Dec 15.

6.

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer.

O'Flaherty L, Wikman H, Pantel K.

Transl Lung Cancer Res. 2017 Aug;6(4):431-443. doi: 10.21037/tlcr.2017.07.03. Review.

7.

Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases.

Mohme M, Riethdorf S, Dreimann M, Werner S, Maire CL, Joosse SA, Bludau F, Mueller V, Neves RPL, Stoecklein NH, Lamszus K, Westphal M, Pantel K, Wikman H, Eicker SO.

Sci Rep. 2017 Aug 3;7(1):7196. doi: 10.1038/s41598-017-07649-z.

8.

Nanoplatforms for Circulating Tumor Cell Detection in Lung Cancer.

Wikman H, Pantel K.

Clin Chem. 2017 Aug;63(8):1318-1320. doi: 10.1373/clinchem.2017.272682. Epub 2017 Jun 6. No abstract available.

9.

PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.

Lehtinen L, Vainio P, Wikman H, Huhtala H, Mueller V, Kallioniemi A, Pantel K, Kronqvist P, Kallioniemi O, Carpèn O, Iljin K.

J Pathol Clin Res. 2017 Apr 4;3(2):123-138. doi: 10.1002/cjp2.69. eCollection 2017 Apr.

10.

Role of HYAL1 expression in primary breast cancer in the formation of brain metastases.

Witzel I, Marx AK, Müller V, Wikman H, Matschke J, Schumacher U, Stürken C, Prehm P, Laakmann E, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L.

Breast Cancer Res Treat. 2017 Apr;162(3):427-438. doi: 10.1007/s10549-017-4135-6. Epub 2017 Feb 6.

PMID:
28168629
11.

PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression.

Hohensee I, Chuang HN, Grottke A, Werner S, Schulte A, Horn S, Lamszus K, Bartkowiak K, Witzel I, Westphal M, Matschke J, Glatzel M, Jücker M, Pukrop T, Pantel K, Wikman H.

Oncotarget. 2017 Jan 24;8(4):6155-6168. doi: 10.18632/oncotarget.14047.

12.

Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells.

Babayan A, Alawi M, Gormley M, Müller V, Wikman H, McMullin RP, Smirnov DA, Li W, Geffken M, Pantel K, Joosse SA.

Oncotarget. 2016 Jul 19;8(34):56066-56080. doi: 10.18632/oncotarget.10701. eCollection 2017 Aug 22.

13.

Characterization of different CTC subpopulations in non-small cell lung cancer.

Hanssen A, Wagner J, Gorges TM, Taenzer A, Uzunoglu FG, Driemel C, Stoecklein NH, Knoefel WT, Angenendt S, Hauch S, Atanackovic D, Loges S, Riethdorf S, Pantel K, Wikman H.

Sci Rep. 2016 Jun 15;6:28010. doi: 10.1038/srep28010.

14.

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells.

Hvichia GE, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, Müller V, Loges S, Neves RP, Stoecklein NH, Wikman H, Riethdorf S, Pantel K, Gorges TM.

Int J Cancer. 2016 Jun 15;138(12):2894-904. doi: 10.1002/ijc.30007. Epub 2016 Feb 26.

15.

Breast cancer brain metastases: biology and new clinical perspectives.

Witzel I, Oliveira-Ferrer L, Pantel K, Müller V, Wikman H.

Breast Cancer Res. 2016 Jan 19;18(1):8. doi: 10.1186/s13058-015-0665-1. Review.

16.

Potential Involvement of Jagged1 in Metastatic Progression of Human Breast Carcinomas.

Bednarz-Knoll N, Efstathiou A, Gotzhein F, Wikman H, Mueller V, Kang Y, Pantel K.

Clin Chem. 2016 Feb;62(2):378-86. doi: 10.1373/clinchem.2015.246686. Epub 2015 Dec 31.

17.

Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells.

Gorges TM, Penkalla N, Schalk T, Joosse SA, Riethdorf S, Tucholski J, Lücke K, Wikman H, Jackson S, Brychta N, von Ahsen O, Schumann C, Krahn T, Pantel K.

Clin Cancer Res. 2016 May 1;22(9):2197-206. doi: 10.1158/1078-0432.CCR-15-1416. Epub 2015 Dec 14.

18.

Disseminated Tumor Cells Persist in the Bone Marrow of Breast Cancer Patients through Sustained Activation of the Unfolded Protein Response.

Bartkowiak K, Kwiatkowski M, Buck F, Gorges TM, Nilse L, Assmann V, Andreas A, Müller V, Wikman H, Riethdorf S, Schlüter H, Pantel K.

Cancer Res. 2015 Dec 15;75(24):5367-77. doi: 10.1158/0008-5472.CAN-14-3728. Epub 2015 Nov 16.

19.

Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells.

Werner S, Stamm H, Pandjaitan M, Kemming D, Brors B, Pantel K, Wikman H.

BMC Cancer. 2015 Nov 11;15:896. doi: 10.1186/s12885-015-1907-4.

20.

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.

Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M.

Oncotarget. 2015 Dec 1;6(38):40836-49. doi: 10.18632/oncotarget.5696.

21.

Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer.

Hanssen A, Loges S, Pantel K, Wikman H.

Front Oncol. 2015 Sep 22;5:207. doi: 10.3389/fonc.2015.00207. eCollection 2015. Review.

22.

Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression.

Bednarz-Knoll N, Nastały P, Żaczek A, Stoupiec MG, Riethdorf S, Wikman H, Müller V, Skokowski J, Szade J, Sejda A, Wełnicka-Jaśkiewicz M, Pantel K.

Oncotarget. 2015 Sep 29;6(29):26789-803. doi: 10.18632/oncotarget.4628.

23.

Relevance of βGal-βGalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients.

Milde-Langosch K, Schütze D, Oliveira-Ferrer L, Wikman H, Müller V, Lebok P, Pantel K, Schröder C, Witzel I, Schumacher U.

Breast Cancer Res Treat. 2015 Jun;151(3):515-28. doi: 10.1007/s10549-015-3425-0. Epub 2015 May 15.

PMID:
25975956
24.

Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2.

Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, Kemming D, Wood AW, Edgren H, Neubauer H, Streichert T, Riethdorf S, Bedi U, Baccelli I, Jücker M, Eils R, Fehm T, Trumpp A, Johnsen SA, Klefström J, Wilmanns M, Müller V, Pantel K, Wikman H.

Cancer Discov. 2015 May;5(5):506-19. doi: 10.1158/2159-8290.CD-14-1042. Epub 2015 Feb 25.

25.

Loss of 4q21.23-22.1 is a prognostic marker for disease free and overall survival in non-small cell lung cancer.

Uzunoglu FG, Dethlefsen E, Hanssen A, Wrage M, Deutsch L, Harms-Effenberger K, Vashist YK, Reeh M, Sauter G, Simon R, Bockhorn M, Pantel K, Izbicki JR, Wikman H.

PLoS One. 2014 Dec 11;9(12):e113315. doi: 10.1371/journal.pone.0113315. eCollection 2014.

26.

Identification of HERC5 and its potential role in NSCLC progression.

Wrage M, Hagmann W, Kemming D, Uzunoglu FG, Riethdorf S, Effenberger K, Westphal M, Lamszus K, Kim SZ, Becker N, Izbicki JR, Sandoval J, Esteller M, Pantel K, Risch A, Wikman H.

Int J Cancer. 2015 May 15;136(10):2264-72. doi: 10.1002/ijc.29298. Epub 2014 Nov 9.

27.

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.

Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman H, Pantel K, Schwarzenbach H.

Oncotarget. 2014 Oct 30;5(20):9650-63.

28.

PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis.

LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, de Carvalho FM, Damascena A, Domingos Chinen LT, Rocha RM, Asara JM, Kalluri R.

Nat Cell Biol. 2014 Oct;16(10):992-1003, 1-15. doi: 10.1038/ncb3039. Epub 2014 Sep 21. Erratum in: Nat Cell Biol. 2014 Nov;16(11):1125.

29.

Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients.

Wikman H, Westphal L, Schmid F, Pollari S, Kropidlowski J, Sielaff-Frimpong B, Glatzel M, Matschke J, Westphal M, Iljin K, Huhtala H, Terracciano L, Kallioniemi A, Sauter G, Müller V, Witzel I, Lamszus K, Kemming D, Pantel K.

Oncotarget. 2014 May 30;5(10):3076-87.

30.

Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.

Hohensee I, Lamszus K, Riethdorf S, Meyer-Staeckling S, Glatzel M, Matschke J, Witzel I, Westphal M, Brandt B, Müller V, Pantel K, Wikman H.

Am J Pathol. 2013 Jul;183(1):83-95. doi: 10.1016/j.ajpath.2013.03.023. Epub 2013 May 9.

PMID:
23665199
31.

C-X-C motif receptor 2, endostatin and proteinase-activated receptor 1 polymorphisms as prognostic factors in NSCLC.

Uzunoglu FG, Yavari N, Bohn BA, Nentwich MF, Reeh M, Pantel K, Perez D, Tsui TY, Bockhorn M, Mann O, Izbicki JR, Wikman H, Vashist YK.

Lung Cancer. 2013 Jul;81(1):123-9. doi: 10.1016/j.lungcan.2013.03.007. Epub 2013 Mar 30.

PMID:
23548249
32.

VEGFR-2, CXCR-2 and PAR-1 germline polymorphisms as predictors of survival in pancreatic carcinoma.

Uzunoglu FG, Kolbe J, Wikman H, Güngör C, Bohn BA, Nentwich MF, Reeh M, König AM, Bockhorn M, Kutup A, Mann O, Izbicki JR, Vashist YK.

Ann Oncol. 2013 May;24(5):1282-90. doi: 10.1093/annonc/mds634. Epub 2013 Jan 4.

PMID:
23293110
33.

Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.

Wikman H, Sielaff-Frimpong B, Kropidlowski J, Witzel I, Milde-Langosch K, Sauter G, Westphal M, Lamszus K, Pantel K.

PLoS One. 2012;7(10):e47537. doi: 10.1371/journal.pone.0047537. Epub 2012 Oct 31.

34.

Circulating tumor-derived biomarkers in lung cancer.

Taenzer A, Alix-Panabières C, Wikman H, Pantel K.

J Thorac Dis. 2012 Oct;4(5):448-9. doi: 10.3978/j.issn.2072-1439.2012.08.17. No abstract available.

35.

Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos-exposed patients.

Nymark P, Aavikko M, Mäkilä J, Ruosaari S, Hienonen-Kempas T, Wikman H, Salmenkivi K, Pirinen R, Karjalainen A, Vanhala E, Kuosma E, Anttila S, Kettunen E.

Mol Oncol. 2013 Feb;7(1):29-40. doi: 10.1016/j.molonc.2012.07.006. Epub 2012 Aug 7.

36.

Relevance of PTEN loss in brain metastasis formation in breast cancer patients.

Wikman H, Lamszus K, Detels N, Uslar L, Wrage M, Benner C, Hohensee I, Ylstra B, Eylmann K, Zapatka M, Sauter G, Kemming D, Glatzel M, Müller V, Westphal M, Pantel K.

Breast Cancer Res. 2012 Mar 19;14(2):R49.

37.

Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.

Uzunoglu FG, Kaufmann C, Wikman H, Güngör C, Bohn BA, Nentwich MF, Reeh M, Pantel K, Bockhorn M, Kutup A, Mann O, Izbicki JR, Vashist YK.

Ann Surg Oncol. 2012 Jul;19(7):2159-68. doi: 10.1245/s10434-012-2227-4. Epub 2012 Mar 7.

PMID:
22395975
38.

Opposite roles of FOXA1 and NKX2-1 in lung cancer progression.

Deutsch L, Wrage M, Koops S, Glatzel M, Uzunoglu FG, Kutup A, Hinsch A, Sauter G, Izbicki JR, Pantel K, Wikman H.

Genes Chromosomes Cancer. 2012 Jun;51(6):618-29. doi: 10.1002/gcc.21950. Epub 2012 Mar 2.

PMID:
22383183
39.

15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells.

Lehtinen L, Vainio P, Wikman H, Reemts J, Hilvo M, Issa R, Pollari S, Brandt B, Oresic M, Pantel K, Kallioniemi O, Iljin K.

J Pathol. 2012 Mar;226(4):674-86. doi: 10.1002/path.3956. Epub 2012 Jan 17.

PMID:
22072156
40.

Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.

Hein S, Müller V, Köhler N, Wikman H, Krenkel S, Streichert T, Schweizer M, Riethdorf S, Assmann V, Ihnen M, Beck K, Issa R, Jänicke F, Pantel K, Milde-Langosch K.

Breast Cancer Res Treat. 2011 Sep;129(2):347-60. doi: 10.1007/s10549-010-1219-y. Epub 2010 Oct 23.

PMID:
20972617
41.

DNA copy number loss and allelic imbalance at 2p16 in lung cancer associated with asbestos exposure.

Kettunen E, Aavikko M, Nymark P, Ruosaari S, Wikman H, Vanhala E, Salmenkivi K, Pirinen R, Karjalainen A, Kuosma E, Anttila S.

Br J Cancer. 2009 Apr 21;100(8):1336-42. doi: 10.1038/sj.bjc.6605012. Epub 2009 Mar 31.

42.

Meta- and pooled analysis of GSTP1 polymorphism and lung cancer: a HuGE-GSEC review.

Cote ML, Chen W, Smith DW, Benhamou S, Bouchardy C, Butkiewicz D, Fong KM, Gené M, Hirvonen A, Kiyohara C, Larsen JE, Lin P, Raaschou-Nielsen O, Povey AC, Reszka E, Risch A, Schneider J, Schwartz AG, Sorensen M, To-Figueras J, Tokudome S, Pu Y, Yang P, Wenzlaff AS, Wikman H, Taioli E.

Am J Epidemiol. 2009 Apr 1;169(7):802-14. doi: 10.1093/aje/kwn417. Epub 2009 Feb 24.

43.

Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion.

Wrage M, Ruosaari S, Eijk PP, Kaifi JT, Hollmén J, Yekebas EF, Izbicki JR, Brakenhoff RH, Streichert T, Riethdorf S, Glatzel M, Ylstra B, Pantel K, Wikman H.

Clin Cancer Res. 2009 Mar 1;15(5):1566-74. doi: 10.1158/1078-0432.CCR-08-2188. Epub 2009 Feb 10.

44.

Molecular alterations at 9q33.1 and polyploidy in asbestos-related lung cancer.

Nymark P, Kettunen E, Aavikko M, Ruosaari S, Kuosma E, Vanhala E, Salmenkivi K, Pirinen R, Karjalainen A, Knuutila S, Wikman H, Anttila S.

Clin Cancer Res. 2009 Jan 15;15(2):468-75. doi: 10.1158/1078-0432.CCR-08-1852.

45.

Pathways affected by asbestos exposure in normal and tumour tissue of lung cancer patients.

Ruosaari S, Hienonen-Kempas T, Puustinen A, Sarhadi VK, Hollmén J, Knuutila S, Saharinen J, Wikman H, Anttila S.

BMC Med Genomics. 2008 Nov 11;1:55. doi: 10.1186/1755-8794-1-55.

46.

Cancer micrometastasis and tumour dormancy.

Wikman H, Vessella R, Pantel K.

APMIS. 2008 Jul-Aug;116(7-8):754-70. doi: 10.1111/j.1600-0463.2008.01033.x. Review.

PMID:
18834417
47.

Review: Biological relevance of disseminated tumor cells in cancer patients.

Riethdorf S, Wikman H, Pantel K.

Int J Cancer. 2008 Nov 1;123(9):1991-2006. doi: 10.1002/ijc.23825. Review.

48.

Molecular and genetic changes in asbestos-related lung cancer.

Nymark P, Wikman H, Hienonen-Kempas T, Anttila S.

Cancer Lett. 2008 Jun 28;265(1):1-15. doi: 10.1016/j.canlet.2008.02.043. Epub 2008 Mar 24. Review.

PMID:
18364247
49.

Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer.

Wikman H, Ruosaari S, Nymark P, Sarhadi VK, Saharinen J, Vanhala E, Karjalainen A, Hollmén J, Knuutila S, Anttila S.

Oncogene. 2007 Jul 12;26(32):4730-7. Epub 2007 Feb 12.

PMID:
17297452
50.

Identification of specific gene copy number changes in asbestos-related lung cancer.

Nymark P, Wikman H, Ruosaari S, Hollmén J, Vanhala E, Karjalainen A, Anttila S, Knuutila S.

Cancer Res. 2006 Jun 1;66(11):5737-43.

Supplemental Content

Loading ...
Support Center